The biggest winner of the 2020 innovation drug was approved: Novartis.

In the first half of 2020, the FDA approved 25 new drugs (including new molecular entities and new biological products), up from 14 in the same period in 2019, and the EUROPEAN Union EMA approved 21 new drugs (including new active substances, excluding generics, biosimilars and vaccines)) was the same as in the same period in 2019, with China's NMPA approving 27 new drugs (including chemical sinops 1 and 5.1, biologics 1 and 2, Chinese medicine and vaccines), an increase from 21 in the same period in 2019This paper counts each regulatory agency's approvals separately, and counts the six companies that approved the largest number of new drugs in the first half of 2020 from the corporate dimensionNovartis was the biggest winner of the approved innovative drug in the first half of 2020, with seven approvalsThis was followed by Lilly, Sanofi and Sanofi each with four new drug approvals, and Roche, Pfizer and BMS each with three new drug approvalsIn the first half of 2020, the largest number of innovative drugs approved enterprises below the above six enterprises approved new drugs to make a presentation1Novartis in 2019 is the European and American regulatory market to win the largest number of new drugs (10), in the first half of 2020, Novartis in the United States has 2 new drugs approved, China has 1 new drug approved, the European Union has 4 new drugs approved, ranking first in the EU approval listIn the first half of the year, Novartis rare disease new drug Isturisa was approved in the United States and the European Union in March, a new generation of anti-VEGF ophthalmology drug Beovu, SMA gene therapy in the European Union, a new generation of S1PR regulator Simod was approved in the European Union, China and Japan, the first METex14 advanced non-small cell lung cancer drug Tabrecta also received FDA approvalSource: NextPharma 2Lilly Lilly approved four new drug applications in the first half of the year, including Retevmo, the first FDA-approved treatment for patients with advanced lung cancer and thyroid cancer for the RET-driven geneSource: NextPharma 3Sanofi Sanofi approved four new drug applications in the first half of the year, of which, two new drugs approved in China are clinically urgentneeded overseas medicationsThe new multiple myeloma drug, approved in the United States and the European Union, is a CD38 monotorineSource: NextPharma 4Roche Roche approved three new drug applications in the first half of the year, and 2 in China, namely, The ADC drug Enmequita zuma and PD-L1 drug atlizumabsource: NextPharma 5Pfizer Pfizer also approved a total of 3 new drug applications in the first half of the year, China approved chlorobenzene acid for clinical urgent need for overseas drugs, the European Union approved the new drug of special dermatitis crespharis cressis has also submitted a listing application in China, and has been included in the clinical urgent need for new drugs, is expected to be approved in China this year Source: NextPharma 6.BMS BMS a total of 3 new drug applications approved in the first half of the year, China's approved Abassup equity has been authorized to the first sound pharmaceutical industry, and the other two are approved by the United States and the European Union Ozamod, the drug bmS heavy gold acquisition of the new base of a new multi-sclerosis drug Source: Although NextPharma is a global epidemic of new crown pneumonia in the first half of 2020, it has not been affected by the number of new drugs approved by drug regulators in the Us and Europe It is also worth noting that the date of approval of imported new drugs in China has gradually coincided with the global, for example, Novartis's Sinimod was approved by the FDA as early as March 2019, approved by the European Union in January 2020 and approved in China in May 2020